All terms in EFO
| Label | Id | Description |
|---|---|---|
| fetal anticonvulsant syndrome | MONDO_0018262 | |
| toxic or drug-related embryofetopathy | MONDO_0016677 | [Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.] |
| obsolete_anomaly of puberty or/and menstrual cycle of genetic origin | Orphanet_202940 | |
| glossodynia | MONDO_0043237 | [Painful sensations in the tongue, including a sensation of burning.] |
| obsolete_syndromic microphthalmia | Orphanet_202948 | |
| congenital muscular dystrophy without intellectual disability | MONDO_0018279 | |
| disorder of O-mannosylglycan synthesis | MONDO_0017745 | |
| muscular dystrophy-dystroglycanopathy | MONDO_0018276 | |
| congenital muscular dystrophy with intellectual disability | MONDO_0018278 | |
| GM3 synthase deficiency | MONDO_0018274 | [GM3 synthase deficiency is characterized by recurrent seizures (epilepsy) and problems with brain development. Within the first few weeks after birth, affected infants become irritable and develop feeding difficulties and vomiting that prevent them from growing and gaining weight at the usual rate. Seizures begin within the first year of life and worsen over time. Multiple types of seizures are possible, including generalized tonic-clonic seizures (also known as grand mal seizures), which cause muscle rigidity, convulsions, and loss of consciousness. Some affected children also experience prolonged episodes of seizure activity called nonconvulsive status epilepticus. The seizures associated with GM3 synthase deficiency tend to be resistant (refractory) to treatment with antiseizure medications.] |
| inborn disorder of glycosphingolipid and glycosylphosphatidylinositol anchor glycosylation | MONDO_0017748 | |
| skin pigmentation disorder | MONDO_0019288 | [A pigmentation disease that involves the zone of skin.] |
| Cafeteria roenbergensis | NCBITaxon_33653 | |
| congenital muscular dystrophy with cerebellar involvement | MONDO_0018277 | |
| mitochondrial complex II deficiency, nuclear type | MONDO_0031230 | |
| congenital muscular dystrophy | MONDO_0019950 | [A muscular dystrophy that is characterized by diminished muscle tone (hypotonia), progressive muscle weakness and degeneration (atrophy), abnormally fixed joints, spinal rigidity, and delays in reaching motor milestones such as sitting or standing unassisted.] |
| peripheral primitive neuroectodermal tumor | MONDO_0018271 | [A small round cell tumor with neural differentiation arising from the soft tissues or bone.] |
| primitive neuroectodermal tumor | EFO_0005235 | [A malignant neoplasm that originates in the neuroectoderm. The neuroectoderm constitutes the portion of the ectoderm of the early embryo that gives rise to the central and peripheral nervous systems and includes some glial cell precursors.] |
| Ewing sarcoma/peripheral primitive neuroectodermal tumor | MONDO_0021038 | [A spectrum of malignant tumors, affecting mostly males under age 20, characterized morphologically by the presence of small round cells. Ewing sarcoma and peripheral primitive neuroectodermal tumor represent the ends of a spectrum, with Ewing sarcoma lacking evidence of neural differentiation and the markers that characterize the peripheral primitive neuroectodermal tumor. Ewing sarcoma and peripheral primitive neuroectodermal tumor may share cytogenetic abnormalities, proto-oncogene expression, cell culture and immunohistochemical abnormalities. These tumors may occur in the soft tissues or the bones. Pain and the presence of a mass are the most common clinical symptoms.] |
| Trypanosoma brucei brucei | NCBITaxon_5702 |